2-(4-甲氧基苯基)-1,3-恶唑-4-羧酸 | 1065102-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-甲氧基苯基)-1,3-恶唑-4-羧酸
• 英文名称: 2-(4-methoxyphenyl)oxazole-4-carboxylic acid
• 英文别名: 2-(4-methoxyphenyl)oxazoline-4-carboxylic acid；2-(4-methoxyphenyl)-1,3-oxazole-4-carboxylic acid
• CAS: 1065102-54-6
• 化学式: C₁₁H₉NO₄
• 分子量: 219.197
• InChiKey: PTRJKSHNPPIQBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-甲氧基苯基)-1,3-恶唑-4-羧酸 在 4-二甲氨基吡啶 、 copper(l) iodide 、 sodium azide 、 cesiumhydroxide monohydrate 、 Maruoka catalyst 、 sodium cyanoborohydride 、 溶剂黄146 、 sodium ascorbate 、 N,N'-二甲基乙二胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 甲苯 、 叔丁醇 为溶剂， 反应 94.0h， 生成 (R)-tert-butyl 2-(4-azidobenzyl)-3-hydroxy-2-(4-methoxybenzylamino)propanoate
  参考文献：
  名称：

  Enantioselective synthesis of α-benzylated lanthionines and related tripeptides for biological incorporation into E. coli peptidoglycan

  摘要：

  我们合成了修饰三肽 (S)-Ala-δ-(R)-Glu-X，其中 X = δ-苄基或δ-(4-叠氮基苄基)兰硫鎓的(R,S)或(R,R)非对映异构体。化学策略涉及 4-MeO-苯基噁唑啉的对映选择性烷基化。烷基化的噁唑啉还原开放，然后进行环化和氧化，最终得到四个 PMB 保护的氨基磺酸盐。随后通过去除 PMB、Boc 保护和半胱氨酸甲酯的区域选择性开环，得到了受保护的镧系元素。这些化合物通过一锅法进一步转化为相应的受保护三肽。经过酯和 Boc 去保护后，这四种三肽被评估为天然三肽 (S)-Ala-γ-(R)-Glu-meso-A2pm 的潜在类似物。对这些化合物进行了评估，以便通过生物合成循环途径将其引入大肠杆菌的肽聚糖中。利用纯化的金霉素肽连接酶（Mpl），成功地从含有δ-苄基兰硫氨酸的三肽体外生物合成了 UDP-MurNAc-三肽。在不同的测试条件下，大肠杆菌 W7 都没有发生生物卟啉化，这可能是由于 C 端氨基酸 Cδ 碳上的苄基过大所致。

  DOI：

  10.1039/c4ob01476f
• 作为产物：
  描述：

  2-(4-甲氧基苯基)-噁唑-4-羧酸乙酯 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 2-(4-甲氧基苯基)-1,3-恶唑-4-羧酸
  参考文献：
  名称：

  潜在的PDE4抑制剂苯基取代的呋喃和恶唑羧酸衍生物的合成及生物活性

  摘要：

  在本研究中，设计并合成了一系列5-苯基-2-呋喃和4-苯基-2-恶唑衍生物，作为4型磷酸二酯酶（PDE4）抑制剂。体外结果表明，合成的化合物对PDE4B表现出相当大的抑制活性，并阻断LPS诱导的TNF- α释放。在设计的化合物中，化合物5j在体外酶法检测中对PDE4的IC 50值（1.4μM）低于母体咯利普兰（2.0μM），在体内也显示出良好的LPS诱发的哮喘/ COPD和败血症动物模型中的活性降低。对接结果表明，在苯环对位引入甲氧基，表现出与PDE4B的金属结合口袋结构域良好的相互作用，这有助于增强抑制活性。

  DOI：

  10.1016/j.ejmech.2020.112795

文献信息

• Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors
  作者：Yinuo Lin、Wasim Ahmed、Min He、Xuwen Xiang、Riyuan Tang、Zi-Ning Cui

  DOI：10.1016/j.ejmech.2020.112795

  日期：2020.12

  In this present study, a series of 5-phenyl-2-furan and 4-phenyl-2-oxazole derivatives were designed and synthesized as phosphodiesterase type 4 (PDE4) inhibitors. In vitro results showed that the synthesized compounds exhibited considerable inhibitory activity against PDE4B and blockade of LPS-induced TNF-α release. Among the designed compounds, Compound 5j exhibited lower IC50 value (1.4 μM) against

  在本研究中，设计并合成了一系列5-苯基-2-呋喃和4-苯基-2-恶唑衍生物，作为4型磷酸二酯酶（PDE4）抑制剂。体外结果表明，合成的化合物对PDE4B表现出相当大的抑制活性，并阻断LPS诱导的TNF- α释放。在设计的化合物中，化合物5j在体外酶法检测中对PDE4的IC 50值（1.4μM）低于母体咯利普兰（2.0μM），在体内也显示出良好的LPS诱发的哮喘/ COPD和败血症动物模型中的活性降低。对接结果表明，在苯环对位引入甲氧基，表现出与PDE4B的金属结合口袋结构域良好的相互作用，这有助于增强抑制活性。
• Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors
  作者：Ya-Sheng Li、De-Kun Hu、Dong-Sheng Zhao、Xing-Yu Liu、Hong-Wei Jin、Gao-Peng Song、Zi-Ning Cui、Lian-Hui Zhang

  DOI：10.1016/j.bmc.2017.01.047

  日期：2017.3

  In this study, a series of pyrazole derivatives containing 4-phenyl-2-oxazole moiety were designed and synthesized in a concise way, some of which exhibited considerable inhibitory activity against PDE4B and blockade of LPS-induced TNF-α release. Compound 4c displayed the strongest inhibition activity (IC50=1.6±0.4μM) and good selectivity against PDE4B. Meanwhile, compound 4c showed good in vivo activity

  在这项研究中，以简明的方式设计和合成了一系列含有4-苯基-2-恶唑部分的吡唑衍生物，其中一些对PDE4B表现出相当大的抑制活性，并阻断了LPS诱导的TNF-α释放。化合物4c显示出最强的抑制活性（IC50 = 1.6±0.4μM）和对PDE4B的良好选择性。同时，化合物4c在LPS诱导的哮喘/ COPD和败血症动物模型中显示出良好的体内活性。初步的结构-活性关系研究表明，3,5-二甲基吡唑残基对于生物活性至关重要，苯环上的取代基R1也影响了活性。对接结果表明，化合物4c分别使用酰肼骨架（CONN）和吡唑环在形成完整的氢键和π-π堆积相互作用中起关键作用，与PDE4B蛋白结合。而分子的其余部分扩展到催化域中以阻止cAMP的访问，并形成了抑制PDE4B的基础。基于初步的结构-活性关系和分子模型研究，化合物4c有望作为进一步研究的先导化合物。
• Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors
  作者：Johanna Senger、Jelena Melesina、Martin Marek、Christophe Romier、Ina Oehme、Olaf Witt、Wolfgang Sippl、Manfred Jung

  DOI：10.1021/acs.jmedchem.5b01493

  日期：2016.2.25

  Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several nonhistone proteins. Here we report the preparation of thiazole-, oxazole-, and oxadiazole-containing biarylhydroxamic acids by a short synthetic procedure. We identified them as selective HDAC6 inhibitors by investigating the inhibition of B recombinant HDAC enzymes and the protein acetylation in cells by Western blotting (tubulin vs histone acetylation). The most active compounds exhibited nanomolar potency and high selectivity for HDAC6. For example, an oxazole hydroxamate inhibits HDAC6 with an IC50 of 59 nM and has a selectivity index of >200 against HDAC1 and HDAC8. This is the first report showing that the nature of a heterocycle directly connected to a zinc binding group (ZBG) can be used to modulate subtype selectivity and potency for HDAC6 inhibitors to such an extent. We rationalize the high potency and selectivity of the oxazoles by molecular modeling and docking.
• <i>N</i>-((1-Benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl)arylamide as a New Scaffold that Provides Rapid Access to Antimicrotubule Agents: Synthesis and Evaluation of Antiproliferative Activity Against Select Cancer Cell Lines
  作者：Jonathan A. Stefely、Rahul Palchaudhuri、Patricia A. Miller、Rebecca J. Peterson、Garrett C. Moraski、Paul J. Hergenrother、Marvin J. Miller

  DOI：10.1021/jm1000979

  日期：2010.4.22

  A series of N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamides was synthesized by copper-catalyzed azide alkyne cycloaddition (CuAAC) and afforded inhibitors of cancer cell growth. For example, compound 13e had an IC50 of 46 nM against MCF-7 human breast tumor cells. Structure activity relationship (SA R) studies demonstrated that (i) meta-phenoxy substitution of the N-1-benzyl group is important for antiproliferative activity and (ii) a variety of heterocyclic substitutions for the aryl group of the arylamide are tolerated. In silico COMPARE analysis of antiproliferative activity against the NCI-60 human tumor cell line panel revealed a correlation to clinically useful antimicrotubule agents such as paclitaxel and vincristine. This in silico correlation was supported by (i) in vitro inhibition of tubulin polymerization, (ii) G(2)/M-phase arrest in HeLa cells as assessed by flow cytometry, and (iii) perturbation of normal microtubule activity in HeLa cells as observed by confocal microscopy. The results demonstrate that N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide is a readily accessible small molecule scaffold for compounds that inhibit tubulin polymerization and tumor cell growth.
• Enantioselective synthesis of α-benzylated lanthionines and related tripeptides for biological incorporation into E. coli peptidoglycan
  作者：Thibaut Denoël、Astrid Zervosen、Christian Lemaire、Bernard Joris、Mireille Hervé、Didier Blanot、Guillermo Zaragoza、André Luxen

  DOI：10.1039/c4ob01476f

  日期：——

  The synthesis of modified tripeptides (S)-Ala-γ-(R)-Glu-X, where X = (R,S) or (R,R) diastereomers of α-benzyl or α-(4-azidobenzyl)lanthionine, was carried out. The chemical strategy involved the enantioselective alkylation of a 4-MeO-phenyloxazoline. The reductive opening of the alkylated oxazolines, followed by cyclization and oxidation, led to four PMB-protected sulfamidates. Subsequent PMB removal, Boc protection and regioselective opening with cysteine methyl ester led to protected lanthionines. These compounds were further converted in a one pot process to the corresponding protected tripeptides. After ester and Boc deprotection, the four tripeptides were evaluated as potential analogues of the natural tripeptide (S)-Ala-γ-(R)-Glu-meso-A2pm. These compounds were evaluated for introduction, by means of the biosynthetic recycling pathway, into the peptidoglycan of Escherichia coli. A successful in vitro biosynthesis of UDP-MurNAc-tripeptides from the tripeptides containing α-benzyl lanthionine was achieved using purified murein peptide ligase (Mpl). Bioincorporation into E. coli W7 did not occur under different tested conditions probably due to the bulky benzyl group at the Cα carbon of the C-terminal amino acid.

  我们合成了修饰三肽 (S)-Ala-δ-(R)-Glu-X，其中 X = δ-苄基或δ-(4-叠氮基苄基)兰硫鎓的(R,S)或(R,R)非对映异构体。化学策略涉及 4-MeO-苯基噁唑啉的对映选择性烷基化。烷基化的噁唑啉还原开放，然后进行环化和氧化，最终得到四个 PMB 保护的氨基磺酸盐。随后通过去除 PMB、Boc 保护和半胱氨酸甲酯的区域选择性开环，得到了受保护的镧系元素。这些化合物通过一锅法进一步转化为相应的受保护三肽。经过酯和 Boc 去保护后，这四种三肽被评估为天然三肽 (S)-Ala-γ-(R)-Glu-meso-A2pm 的潜在类似物。对这些化合物进行了评估，以便通过生物合成循环途径将其引入大肠杆菌的肽聚糖中。利用纯化的金霉素肽连接酶（Mpl），成功地从含有δ-苄基兰硫氨酸的三肽体外生物合成了 UDP-MurNAc-三肽。在不同的测试条件下，大肠杆菌 W7 都没有发生生物卟啉化，这可能是由于 C 端氨基酸 Cδ 碳上的苄基过大所致。